Changan Automobile acts as contract manufacturer for us.
Business · p. 149
We maintain oversight of all outsourced manufacturing activities and conduct final acceptance inspections to ensure compliance with our product, process and quality standards.
In 2023, 2024 and 2025, products manufactured by CMOs accounted for approximately 60.9%, 44.2% and 36.9% of our total revenue attributable to maternity and supplements business line, respectively.
Business · p. 145
Our selection of CMOs is based on stringent quality control standards, compliance with food safety regulations, and geographic proximity to key markets.
Business · p. 145
We maintain full oversight of product specifications, raw material sourcing and quality assurance protocols to ensure consistency across all production channels.
In 2023, 2024 and 2025, our outsourcing services costs amounted to RMB31.6 million, RMB24.3 million and RMB40.9 million, respectively, which accounted for 9.0%, 7.4% and 11.8% of our cost of sales during the same periods.
Business · p. 175
We require our contractors to comply with our internal policies and closely monitor their performance.
Business · p. 175
To ensure our contract manufacturers comply with all relevant regulations and protect our intellectual property, we have established a robust control framework.
We operate our proprietary brand business under an asset-light approach and engage independent manufacturers to produce our proprietary brand collections on an OEM basis.
Business · p. 167
Our procurement team works closely with our OEM suppliers during each step of the process and conducts quality checks upon final product delivery to ensure that products manufactured by our suppliers meet our quality control standards.
Business · p. 153
We generally enter into framework agreements with our OEM suppliers with terms ranging from 12 to 18 months, and place orders as necessary.
During the Track Record Period and up to the Latest Practicable Date, we collaborated with contract manufacturers for the production of our hardware products.
Business · p. 176
Our cost of sales attributable to outsourced production amounted to RMB63.5 million, RMB137.7 million and RMB195.8 million, representing approximately 44.3%, 57.9% and 71.7% of our cost of sales, for the same years, respectively.
Business · p. 177
Contract manufacturers are required to manufacture our products strictly in accordance with our proprietary hardware design and product specifications.
Our OEM partners provide non-powered chassis platforms and assemble the final vehicles under our integration requirements. We pay OEMs a contract manufacturing fee.
Business · p. 132
We maintain control over key hardware technologies while partnering with selected OEMs for manufacturing.
Financial Information · p. 208
This model reduces our upfront capital expenditure and gives customers more flexibility, especially in vehicle selection, while ensuring our system performance and safety standards are met through design validation.
As of December 31, 2023, 2024 and 2025, we had 94, 45 and 119 third-party marketing service providers.
Business · p. 162
In 2023, 2024 and 2025, our third-party marketing service fees accounted for 29.7%, 9.5% and 25.5% of our revenue in the same year, respectively.
Business · p. 163
Each service provider operates within a designated region, and for each product, we engage only one service provider per county to ensure that each CDC customer is covered exclusively by a single third-party marketing service provider.
For products with higher technological content, more complex production processes, and stronger intellectual property protection requirements, we adhere to in-house production.
Business · p. 151
For products manufactured by third-party manufacturing partners, non-processing production activities, including product design, product R&D, and quality inspection, are still independently carried out by us.
Business · p. 151
We have entered into framework manufacturing agreements with our major third-party manufacturing partners, which set out general terms in respect of key matters such as product quality control, delivery, and confidentiality obligations.
We have adopted outsourcing arrangement for providing auxiliary services in connection with our printing services during the Track Record Period, to supplement internal capacity and support timely delivery.
Business · p. 138
We retain control over final quality assurance and overall project delivery through established supplier selection, quality control and performance assessment procedures.
Business · p. 138
All externally manufactured components are subject to our independent inspection upon delivery, and only qualified components are transferred to our facilities for subsequent assembly, installation and testing.
With respect to our GNSS chips and modules, we primarily focus on R&D, market expansion, and product sales, with all production processes outsourced.
Business · p. 172
In relation to our GNSS modules, we utilize an OEM collaboration model.
Business · p. 172
Although we currently do not operate any manufacturing facilities, we have a number of policies in place to select and continuously evaluate the foundries and ensure compliance with the relevant requirements.
To supplement our in-house manufacturing capacity, we have historically engaged and will continue to engage industry-recognized contract manufacturing organizations (“CMOs”) to empower an optimized resource allocation and cost efficiency.
Business · p. 159
Following the execution of the marketing authorization transfer agreement for Keppra SR, we outsourced the manufacturing and supply of Keppra SR to Anbison and no finished products had been produced as of the Latest Practicable Date.
Business · p. 161
We conduct quality assurance audit programs to monitor and evaluate the services of our CMOs.
During the Track Record Period, we also outsourced certain manufacturing activities to industry-recognized CDMOs in China for preclinical and clinical supply of our drug candidates.
Business · p. 207
As of the Latest Practicable Date, we did not have in-house manufacturing facility that was operational.
Business · p. 209
Given that we do not currently operate in-house manufacturing facilities and relies on established CDMOs with robust infrastructure and quality systems, the scope of internal CMC activities remains manageable.
We employ a fabless business model, hiring third-party foundries and contractors to manufacture, assemble, and test our perceptual interaction solutions.
Business · p. 145
While the assembly and testing are handled externally, we set testing protocols, quality standards and target yield rates.
Business · p. 145
We have established a comprehensive supplier management system to ensure the quality and reliability of externally provided processes, products and services.
Technical services primarily comprise the outsourcing of non-core software modules and on-site technical services, as well as technical consultation services.
Business · p. 158
In order to enhance the focus of our core technical and management personnel on the design and on-site implementation of our products, we outsource certain non-core software modules (such as ERP, warehouse management systems, and database management systems) to companies with extensive experience in relevant fields for collaboration.
Business · p. 158
We also strictly supervise and evaluate the work quality and implementation effectiveness of outsourced personnel during project execution to ensure that our products can be delivered to our customers in a timely, stable, and efficient manner.
We are focusing on the research, design, and development of our products while outsourcing manufacturing to specialized partners.
Business · p. 154
For each year during the Track Record Period, our top 20 manufacturing partners are responsible for approximately 80% of the manufacturing and assembly tasks and they are primarily located in the PRC and Southeast Asia (such as Vietnam and Thailand).
Business · p. 154
Upon completion, all products undergo rigorous inspection by our quality control department before being approved for delivery.
In alignment with industry standards, we engage CROs to conduct and support our preclinical studies and clinical trials under our close supervision and overall management.
Business · p. 184
During the Track Record Period, we cooperated with eight and 11 CROs in 2024 and 2025, respectively, which were all independent third parties of our Group.
Business · p. 185
We ensure CROs and SMOs comply with applicable regulatory requirements and our internal policies through (i) selective engagement of experienced service providers with proven track records; (ii) contractual controls, pursuant to which the agreements require requisite qualifications, compliance with applicable laws and regulations, and periodic quality assurance audits by us; and (iii) ongoing oversight by dedicated clinical project managers through remote monitoring, on-site inspections and milestone reviews.
We have commissioned GMP-compliant third parties for the production of disposables during the Track Record Period, and did not engage in any in-house production of such materials.
Business · p. 190
After the Track Record Period and as of the Latest Practicable Date, we expanded a dedicated production cleanroom for the large-scale production of medical disposables, and had received approval for the expanded production facility.
In 2023, 2024 and 2025, our outsourced costs amounted to RMB2.6 million, RMB2.8 million and RMB3.6 million, respectively, accounting for 3.9%, 3.4% and 1.8% of our total cost of sales in the same respective periods.
Business · p. 152
There was no material delay in delivery of services by our manufacturing partners during the Track Record Period.
For certain campaigns, we engage third-party vendors to execute specific operational tasks, including content production such as photography, videography, graphic design, copywriting and video editing, as well as offline execution such as venue setup and production of promotional materials.
Business · p. 157
we manage the overall project plan and quality, while coordinating and overseeing the delivery of services by such third-party vendors
In line with industry practice, we engage Independent Third Party CROs to conduct and support our process and preclinical research and clinical trials.
Business · p. 161
In 2023, 2024 and 2025, the expenses attributable to CROs were RMB10.3 million, RMB2.1 million and RMB2.2 million, respectively, accounted for 42.5%, 15.0% and 9.3% of our research and development expenses for the same periods, respectively.
Business · p. 162
We closely monitor and manage the activities of these CROs to ensure their work progress and the quality of their work.